From the Boston Globe Business Team
Repligen reports positive test results
May 10, 2007 08:13 AM
Email|
Comments (0)|
Text size
–
+
Repligen Corp. today disclosed positive preliminary test results for a treatment that potentially can make it easier to detect abnormalities in the pancreas.
The Waltham biopharmaceutical company said results were encouraging from a Phase 2 clinical trial to evaluate the use of RG1068, synthetic human secretin, as an agent to improve the assessment of pancreatic duct structures by magnetic resonance imaging, or MRI.
"We are pleased with the successful outcome of our first prospectively defined, blinded, multi-center clinical study to assess the use of secretin to aid in the detection of structural abnormalities of the pancreas," chief executive Walter C. Herlihy said in a statement.
(By Chris Reidy, Globe staff)
